Ulixertinib is primarily used in the field of oncology as an investigational drug targeting cancer treatment. It functions as a potent and selective inhibitor of ERK1/2, which are key components of the MAPK/ERK signaling pathway. This pathway is often dysregulated in various cancers, leading to uncontrolled cell proliferation and survival. By inhibiting ERK1/2, ulixertinib aims to block this pathway, thereby reducing tumor growth and progression. It is being studied in clinical trials for its potential efficacy in treating solid tumors, including melanoma, colorectal cancer, and pancreatic cancer, particularly in cases where other treatments have failed or where mutations in the MAPK pathway are present. The drug represents a promising approach for patients with limited therapeutic options, offering hope for improved outcomes in advanced or refractory cancers.